TECH Stock Might Rise Following the Leo Shipping Announcement

Bio-Techne Corporation TECH recently began shipping the Leo System, powered by Simple Western Technology. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.Leo will enable Bio-Techne’s customers to accelerate their cutting-edge science and bring next-generation therapies to market faster. TECH Stock Likely to Gain From the DevelopmentSince the announcement on March 10, Bio-Techne’s shares dipped 2.3%, closing at $62.90 on Monday. Following its early access launch, the company is experiencing significant customer interest in the next-generation high-throughput simple Western platform, Leo. Accordingly, we expect the recent shipment of Leo to boost the market sentiment toward TECH stock in the upcoming days.Bio-Techne has a market capitalization of $9.24 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.5% revenue improvement. It delivered a trailing four-quarter average earnings surprise of 1.55%. About Bio-Techne’s LeoLeo enables the simultaneous processing of up to 100 samples in a single 3-hour run. It provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Additionally, it features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance. Early adopters are thrilled with Leo’s power. Meanwhile, beta testers praised its robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays. Industry Prospects Favor Bio-TechnePer a Grand View Research report, the global western blotting market size was valued at $1.97 billion in 2024 and is projected to witness a compound annual rate (CAGR) of 6.01% from 2025 to 2030. The rising rate of brain disorders and increasing research initiatives in the biotech and pharma sectors are driving market growth. Image Source: Zacks Investment ResearchOther Recent Developments by Bio-TechneEarlier this month, Bio-Techne’s brand, Asuragen, inked a partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only AmplideX Nanopore Carrier Plus Kit is a new genetic panel that will support software analysis for carrier screening research.  Last month, the company launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with advanced sensitivity and specificity, the Advanced Cell Diagnostics branded RNAscope probe portfolio now covers more than 70,000 unique probes across more than 450 species.TECH Stock Price PerformanceIn the past year, TECH’s shares have lost 19.3% compared with the industry’s decline of 9.9%.TECH’s Zacks Rank and Key PicksBio-Techne currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space are Masimo MASI, Boston Scientific BSX and Cardinal Health CAH. At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each. Masimo’s shares have rallied 30.1% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks